Heart Failure News and Research

RSS

Heart failure (HF) is a condition in which a problem with the structure or function of the heart impairs its ability to supply sufficient blood flow to meet the body's needs. It should not be confused with cardiac arrest or myocardial infarction.

Study finds higher heart attack risk days after cold exposure

Hospital admissions for heart attacks increase after exposure to lower air temperature and cold spells, according to a study published today in JACC, the flagship journal of the American College of Cardiology, and presented at the European Society of Cardiology (ESC) Congress 2024.

1 Sep 2024

Rising resting heart rate over the years linked to shorter lifespan, study show

Study finds that increases in resting heart rate over time significantly raise mortality risk, underscoring heart rate as a key factor in lifespan determination.

1 Sep 2024

New study confirms safety of SGLT2 inhibitors after acute myocardial infarction

The SGLT2 inhibitor empagliflozin confers kidney-protective benefits and can therefore be given safely and effectively to patients when they are hospitalized for acute myocardial infarction (MI), a Mount Sinai-led global team of researchers has shown.

1 Sep 2024

Digital consultations improve medication optimization in heart failure patients

Patients with heart failure, a condition affecting more than 60 million worldwide, are four times more likely to receive the optimal combination of medications after 12 weeks of digital consultations.

1 Sep 2024

Triple-pill combination GMRx2 outperforms standard care in lowering blood pressure

New research shows that a treatment plan based on novel combination of low doses of three anti-hypertensive drugs in a single pill - known as GMRx2 - was superior to a high-quality standard care treatment plan at lowering blood pressure in patients with uncontrolled hypertension.

1 Sep 2024

Evening versus morning dosing of antihypertensive medications provides no added benefits

In two trials, one in frail elderly patients, evening administration of blood pressure (BP)-lowering medications had no clinical benefits over morning administration, according to late-breaking research presented in a Hot Line session today at ESC Congress 2024.

1 Sep 2024

RESHAPE-HF2 trial shows M-TEER as effective treatment for functional mitral regurgitation

Mitral transcatheter edge-to-edge repair (M-TEER) reduced cardiovascular death and heart failure (HF)-related hospitalizations with improved health status in patients with HF and moderate to severe functional mitral regurgitation (FMR), according to late-breaking research presented in a Hot Line session today at ESC Congress 2024.

1 Sep 2024

Timing of blood pressure medication administration does not affect outcomes

Evening administration of blood pressure (BP)-lowering medications did not reduce the risk of cardiovascular events or death compared with morning administration, according to late-breaking research presented in a Hot Line session today at ESC Congress 2024.

1 Sep 2024

MATTERHORN trial finds TEER non-inferior to surgery for secondary mitral regurgitation

There was no difference in efficacy between transcatheter edge-to-edge repair (TEER) and surgery in patients with secondary mitral regurgitation (MR), according to late-breaking research presented in a Hot Line session today at ESC Congress 2024.

1 Sep 2024

T-TEER shows promising outcomes in severe tricuspid regurgitation patients after one year

Tricuspid transcatheter edge-to-edge repair (T-TEER) significantly reduced the severity of secondary tricuspid regurgitation and improved quality of life after 1 year, according to late-breaking research presented in a Hot Line session today at ESC Congress 2024.

1 Sep 2024

TAVI outperforms surgery in reducing complications for women with severe aortic stenosis

Transcatheter aortic valve implantation (TAVI) was superior to surgical aortic valve replacement for reducing death, stroke or rehospitalization in women with severe aortic stenosis, according to late-breaking research presented in a Hot Line session today at ESC Congress 2024.

1 Sep 2024

Semaglutide's impact on cardiovascular health expands beyond weight loss

Semaglutide, the popular anti-obesity medication originally developed to treat diabetes, continues to show cardiovascular benefits beyond weight loss, including reducing risk of death, reducing serious COVID-19 related events and improving heart failure (HF) symptoms, according to six new substudies published in JACC, the flagship journal of the American College of Cardiology.

30 Aug 2024

New ESC guidelines highlight broader approach to managing chronic coronary syndromes

The 2024 ESC Guidelines on the management of chronic coronary syndromes (CCS) include a focus on both larger and smaller blood vessels of the heart; new models to estimate chances of blocked large arteries (so-called obstructive coronary artery disease); optimal selection and sequence of tests; drugs and interventions to prevent disease complications and improve symptoms, and the fundamental role of patient involvement.

30 Aug 2024

Updated atrial fibrillation guidelines focus on risk management and patient-centered care

The 2024 ESC Guidelines for the management of atrial fibrillation, developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS), contain a number of new approaches and treatment-specific recommendations to help manage the surging numbers of patients with AF worldwide.

30 Aug 2024

Major surgery complications unaffected by use of renin-angiotensin system inhibitors

There was no difference in major post-operative complications in patients who continued vs. stopped renin-angiotensin system inhibitors (RASIs) before non-cardiac surgery, according to late-breaking research presented in a Hot Line session today at ESC Congress 2024.

30 Aug 2024

Semaglutide lowers COVID-19-related deaths in cardiovascular patients with obesity

Semaglutide, the popular anti-obesity drug, reduced the rates of COVID-19-related adverse events, including death, in those who had overweight or obesity and established cardiovascular disease without diabetes, according to a new study published in JACC, the flagship journal of the American College of Cardiology.

30 Aug 2024

Vutrisiran shows potential to become the new standard of care for rare heart disease

Vutrisiran significantly improved mortality, cardiovascular events and markers of disease progression in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM), according to late-breaking research presented in a Hot Line session today at ESC Congress 2024.

30 Aug 2024

ESC consensus statement highlights obesity's impact on cardiovascular disease

The ESC Clinical Consensus Statement on Obesity and Cardiovascular Disease, presented at this year's ESC Congress (London, UK, 30 August to 2 September) summarizes current evidence on the epidemiology and etiology of obesity; the interplay between obesity, cardiovascular risk factors and cardiac conditions; the clinical management of patients with cardiac disease and obesity; and weight loss strategies including lifestyle changes, interventional procedures, and anti-obesity medications with particular focus on their impact on cardiometabolic risk and cardiac outcomes.

30 Aug 2024

Discovery of borderzone inflammation offers new avenues for heart failure prevention

Ischemic heart disease is the most common cause of death in the world. It begins with a "heart attack", also known as a myocardial infarction (MI), which causes part of the heart to die due to inadequate coronary blood flow.

29 Aug 2024

Northwestern NUCATS Institute secures $55 million NIH grant for health care advancements

The Northwestern University Clinical and Translational Sciences (NUCATS) Institute has received $55 million in National Institutes of Health (NIH) funding to accelerate the development, evaluation and implementation of improved health care interventions.

29 Aug 2024

Heart Failure News and Research

Further Reading

Study finds higher heart attack risk days after cold exposure

Rising resting heart rate over the years linked to shorter lifespan, study show

New study confirms safety of SGLT2 inhibitors after acute myocardial infarction

Digital consultations improve medication optimization in heart failure patients

Triple-pill combination GMRx2 outperforms standard care in lowering blood pressure

Evening versus morning dosing of antihypertensive medications provides no added benefits

RESHAPE-HF2 trial shows M-TEER as effective treatment for functional mitral regurgitation

Timing of blood pressure medication administration does not affect outcomes

MATTERHORN trial finds TEER non-inferior to surgery for secondary mitral regurgitation

T-TEER shows promising outcomes in severe tricuspid regurgitation patients after one year

TAVI outperforms surgery in reducing complications for women with severe aortic stenosis

Semaglutide's impact on cardiovascular health expands beyond weight loss

New ESC guidelines highlight broader approach to managing chronic coronary syndromes

Updated atrial fibrillation guidelines focus on risk management and patient-centered care

Major surgery complications unaffected by use of renin-angiotensin system inhibitors

Semaglutide lowers COVID-19-related deaths in cardiovascular patients with obesity

Vutrisiran shows potential to become the new standard of care for rare heart disease

ESC consensus statement highlights obesity's impact on cardiovascular disease

Discovery of borderzone inflammation offers new avenues for heart failure prevention

Northwestern NUCATS Institute secures $55 million NIH grant for health care advancements

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News